Strontium ranelate in post-menopausal osteoporosis.

Area of Science:

• Endocrinology
• Pharmacology
• Bone Biology

Background:

• Osteoporosis is a major health concern in post-menopausal women.
• Strontium ranelate is a first-line therapeutic agent with proven anti-fracture activity.
• Its unique dual action on bone formation and resorption differentiates it from other osteoporosis treatments.

Purpose of the Study:

• To review the indications, efficacy, side effects, and contraindications of strontium ranelate.
• To compare the anti-fracture efficacy of strontium ranelate with other established osteoporosis therapies.

Main Methods:

• Review of published clinical studies on strontium ranelate.
• Analysis of strontium ranelate's mechanism of action, including calcium receptor activation and OPG/RANKL system influence.
• Evaluation of anti-fracture efficacy in spinal, hip, and extravertebral fractures.

Main Results:

• Strontium ranelate effectively prevents spinal, hip, and extravertebral fractures.
• Spinal fracture efficacy is independent of patient age, baseline BMD, or bone turnover markers.
• Hip fracture efficacy is noted in women with increased fracture risk.
• Increases bone mineral density (BMD) in the lumbar spine and hip.
• Decreases bone resorption markers and increases bone formation markers.
• Administered as a 2.0 g oral dose daily.

Conclusions:

• Strontium ranelate is a valuable therapeutic option for post-menopausal osteoporosis.
• Its dual mechanism of action contributes to its broad anti-fracture efficacy.
• Understanding its specific indications, side effects, and contraindications is crucial for optimal patient management.